The kappa opioid receptor (KOR) system has been implicated in regulation of many behaviors including pain. While there are numerous studies suggesting KOR-regulation of pain being mediated spinally, there have been reports of pain-like behaviors regulated by central KOR signaling. In particular, oxytocin-induced analgesia appears to be mediated by KOR receptors within the ventrolateral periaqueductal gray (vlPAG).
Introduction
As a member of the opioid receptor family, kappa opioid receptor actions have been shown to contribute important roles in analgesia, mood modulation, and drug abuse [1] [2] [3] [4] . They are widely spread throughout the brain, spinal cord, and peripheral systems [5] , and are activated endogenously via the opioid peptide dynorphin [6] . Canonically, KOR-activation involves the inhibition of cyclic AMP production [7] that is mediated through the coupling of the inhibitory G-protein Gi/o [8] . Through the dissociation of the α subunit, which in turns recruit beta arrestin and activate downstream mitogenactivated protein (MAP) kinases that affect transcription factor expression, such as ERK1/2 [9] and p38. The βγ subunit can directly bind and inhibit calcium channels, as well as increase potassium channel conductance [10] . These direct effects on ion channel conductance have been found in several brain regions, ranging from the hippocampus to the dorsal root ganglia [11] . In addition, the phosphorylated KOR activates ERK1/2, as well as phosphoinositide 3 (PI3) kinase and protein kinase A (PKA). Evidence suggests ERK signaling mediates KOR activation-induced attenuation in inhibitor transmission in the BNST [12] . Further, studies have shown that p38 MAP kinase signaling can regulate KOR-mediated inhibition of glutamate transmission in the BNST, and is required for negative affective behaviors that can be blocked by KOR antagonists [13] . The divergence in signaling pathways that mediate the effects of KOR activation are meaningful, as it suggests that biased agonists could be designed to selectively target specific pathways to engender different effects.
The A10dc group DA neurons project from the ventral lateral periaqueductal gray (vlPAG) to the extended amygdala -the bed nucleus of stria terminalis (BNST) and the central amygdala (CeA), areas known to regulate stress, anxiety and pain-related behaviors [14] [15] [16] [17] . Recent studies from our group have found that chemogenetic activation of these vlPAG DA neurons can alter pain-related behaviors. Beyond pain, the fucntion of these neurons has been implicated in arousal [18] and social behavior [19] . Of note, antinociception induced by oxytocin can be blocked by Kappa Opioid Receptor (KOR) antagonism in the PAG [20] . Mechanistically, it has been shown that kappa opioid receptor activation can modulate dopaminergic neurons in the VTA. More specifically, KOR agonist inhibits the VTA DA neurons projecting to the prefrontal cortex [21] . While isolating GABA-mediated inhibitory post-synaptic currents (IPSCs) in the VTA dopamine neurons, the same research group found that opioid agonists inhibited GABAergic transmission. Additionally, GABAergic neurons have been shown to inhibit projection dopamine neurons in the VTA [22] . Similar to the VTA, a population of tonically-active GABAergic neurons have been found in the PAG [23] . Although KORs have been shown to distribute widely in the PAG [24] , specific dopamine neuron-modulation has yet to be probed due to the heterogeneity of the PAG.
The existing behavioral and electrophysiological findings together lead us to the hypothesis that kappa opioid receptors could serve a role in modulating GABAergic inputs onto the vlPAG dopaminergic neurons.
Materials and Methods

Animals and Husbandry
Male TH-eGFP mice on a Swiss Webster background (aged between 5 to 9 weeks)
were bred and used in accordance with an animal use protocol approved by the 
Statistics
Effects of drugs during electrophysiological recordings were evaluated by comparing the magnitude of the dependent measure (mIPSC frequency and amplitude) between the baseline and wash-on (when drug had reached maximal effect at 10 minutes) periods using paired t tests. The effects of antagonists/blockers on the ability of drugs to modulate synaptic transmission were compared using t tests during the washout period.
All values given for drug effects throughout the article are presented as mean ± SEM.
Drugs
Dynorphin A (300 nM), Norbinaltorphimine (Nor-BNI, 100 nM) were purchased from Tocris (Ellisville, MO) and dissolved in distilled water. BAPTA-AM (50µM), Gallein (100µM), and Wortmannin (1µM) were purchased from Tocris and dissolved in DMSO. were purchased from Sigma-Aldrich and dissolved in water. EGTA (100µM) was obtained from Fisher Scienctific and dissolved in 1M NaOH.
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Results
Endogenous KOR agonist Dynorphin A attenuates GABAergic input onto vlPAG DA neurons via presynaptic mechanisms
We first examined the effects of KOR activation on GABA synaptic transmission via bath application of the endogenous ligand dynorphin A (300nM). We first investigated the effects of KOR activation on GABA-mediated mini IPSC and found that KOR activation by its endogenous ligand dynorphin A attenuated inhibitory transmission frequency but not amplitude, suggesting a presynaptic mechanism. This KOR effect is consistent with previous studies in the BNST [12] , and was abolished in the presence of a KOR antagonist nor-BNI in both regions, suggesting KOR-selective mediation. Although all vlPAG DA neurons recorded in this study showed a decrease in GABA-mediated IPSCs, studies in the VTA demonstrated that KOR attenuates inhibitory transmission onto dopamine neurons in a projection target-dependent manner [25, 26] .
Recent evidence showed that GABA afferent region could also play a role in the differential modulation of IPSC by KOR activation [27] . Interestingly, KOR antagonist nor-BNI alone had no effects on spontaneous inhibitory transmission, implying no tonic constitutive kappa modulation on vlPAG DA neurons. In order to verify that the attenuation on GABAergic transmission was indeed mediated by presynaptic signaling of KOR, and not postsynaptic, we blocked GPCR signaling in the recorded postsynaptic cell.
The blockade of postsynaptic GPCR was achieved by the addition of GDPβs in the patching pipette, filling the recorded cell by diffusion. GDPβs is a non-hydrolyzable GDP analogue; it blocks postsynaptic GPCR signaling by preventing the exchange of GDP to GTP, thus preventing G protein activation. We found that the reduction in mIPSCs caused by dynohpin A persisted in the presence of postsynaptic GDPβs, suggesting that postsynaptic KORs were not involved in this observation. Using GDPβs to block postsynaptic GPCRs has been shown effective in the Kash lab where postsynaptic NPY Y1 receptor agonist effects were blocked in its presence. The above evidence demonstrated KOR mediates inhibitory inputs onto vlPAG DA neurons presynaptically, which is not surprising as KOR agonists have been shown to inhibit presynaptic GABA release in other brain regions, such as the BNST [12] , and in the hypothalamus [28] . We continued to examine ion channels that are directly regulated by the KOR βγ subunit.
Opioids depress transmission at many central synapses [29] ; many studies have implicated an kappa opioid-mediated inhibition of presynaptic calcium channels [30, 31] or the activation of presynaptic potassium channels [32, 33] . However, other studies have ruled out the involvement of either channel [26, 34, 35] . In our experiments, it is noteworthy that under zero calcium recording condition, the frequency of mIPSC more than halved in comparison to recordings under normal calcium concentration (refer to In addition, with the removal of calcium, the effect persists, indicating that this inhibition occurs downstream of calcium entry and is calcium-independent. These results raised the possibility that dynorphin A could be activating KORs and directly affect the presynaptic release machinery in the GABAergic inputs onto the vlPAG dopamine neurons. This data is similar to studies on KOR presynaptic inhibition of glutamatergic inputs in the hypothalamus [35] . Although we did not identify the molecular target through which dynorphin inhibits presynaptic GABA, our results are consistent with studies proposing direct modulation of the exocytosis release machinery by the βγ subunit of the Gi/o-coupled GPCR [37, 38] . We continued to rule out the possibility of the actions of phosphorylated KOR, inhibiting PKA and the generation of cAMP. We found a close to significant (p=0.051) decrease in mIPSC frequency upon the application of dynorphin A, consistent with other results that suggest KOR does not inhibit through that actions of PKA.
In this current study, we found that KOR activation presynaptically attenuates inhibitory inputs potentially via the modulation of release machinery. However, KOR influences on excitatory inputs of vlPAG dopamine neurons are unclear. Some studies have shown that KOR does not modulate EPSCs onto other dopamine-rich regions, such as the VTA [39] while others have shown the opposite [40] . Over all cell excitability in the VTA has been shown modulated in a projection-specific manner [21] where only mPFC-projecting VTA dopamine neurons are hyperpolarized by KOR activation, but not NAc-projecting dopamine neurons. It is currently unclear how KOR modulation of vlPAG DA neurons alters behavior. Given the prominent role that the vlPAG plays in pain and negative affect processing, as well as the correlation of KOR functions and emotional behaviors, it is tempting to speculate that KOR actions on this circuit are involved in these processes.
Under the hypothesis that KOR presynaptically inhibits GABAergic inputs, disinhibiting the vlPAG dopamine neurons to potentially modulate projection areas and related behaviors, further elucidation is needed regarding how the KOR modulates the glutamatergic inputs, as well as the overall effect on activity of the vlPAG DA neurons.
Future studies utilizing optogenetics to probe pathway-defined plasticity, as well as applying designer receptors exclusively activated by designer drugs (DREADD) to characterize pathway and cell type-specific modulation will likely shed light on this exciting possibility.
